Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Catalyst Biosciences participates in a conference call with LifeSci Capital » 12:13
01/15/21
01/15
12:13
01/15/21
12:13
BIIB

Biogen

$278.68 /

-1.67 (-0.60%)

, CBIO

Catalyst Biosciences

$6.42 /

-0.24 (-3.60%)

Catalyst's…

Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$6.42 /

-0.24 (-3.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

01/14/21 Truist
Truist says FDA wouldn't be discussing label if not going to approve aducanumab
01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
CBIO Catalyst Biosciences
$6.42 /

-0.24 (-3.60%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$6.42 /

-0.24 (-3.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

  • 18
    Jun
  • 13
    Feb
BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

Over a week ago
Hot Stocks
Nurix Therapeutics expands strategic collaboration with Sanofi » 07:09
01/07/21
01/07
07:09
01/07/21
07:09
NRIX

Nurix Therapeutics

$31.03 /

-0.905 (-2.83%)

, SNY

Sanofi

$47.97 /

-0.69 (-1.42%)

Nurix Therapeutics (NRIX)…

Nurix Therapeutics (NRIX) announced the expansion of its global strategic collaboration with Sanofi (SNY) to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas. Sanofi has exercised its option to expand the number of targets in the collaboration agreement from three to a total of five targets. With the expansion, Nurix receives a payment of $22M, in addition to the previously received upfront payment of $55M. Nurix is also eligible to receive up to approximately $2.5B in total payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and sales milestones. As part of the multi-year collaboration signed in December 2019, Nurix is using its proprietary drug discovery platform, DELigase, that integrates its DNA-encoded libraries and its portfolio of E3 ligases to create small molecules designed to induce degradation of specified drug targets. Sanofi will have exclusive rights and be responsible for clinical development and commercialization of drug candidates resulting from the work while Nurix will retain the option to co-develop and co-promote up to two products in the United States under certain conditions. Nurix will be eligible for royalties on annual net sales of any commercial products that may result from the collaboration, excluding sales in the United States of any products for which Nurix exercises its option to co-develop and co-promote, for which Nurix and Sanofi share U.S. profits and losses evenly, and Nurix will be eligible to receive royalties on ex-U.S. net sales on all optioned products. The collaboration excludes Nurix's wholly owned pipeline for which Nurix retains all rights.

ShowHide Related Items >><<
SNY Sanofi
$47.97 /

-0.69 (-1.42%)

NRIX Nurix Therapeutics
$31.03 /

-0.905 (-2.83%)

NRIX Nurix Therapeutics
$31.03 /

-0.905 (-2.83%)

11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
11/19/20 Baird
Baird starts Nurix Therapeutics with Outperform, $40 price target
11/18/20 Baird
Nurix Therapeutics initiated with an Outperform at Baird
08/18/20
Fly Intel: Top five analyst initiations
SNY Sanofi
$47.97 /

-0.69 (-1.42%)

12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
11/30/20 Morgan Stanley
AbbVie price target raised to $120 from $108 at Morgan Stanley
11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
SNY Sanofi
$47.97 /

-0.69 (-1.42%)

NRIX Nurix Therapeutics
$31.03 /

-0.905 (-2.83%)

  • 24
    Jul
SNY Sanofi
$47.97 /

-0.69 (-1.42%)

SNY Sanofi
$47.97 /

-0.69 (-1.42%)

NRIX Nurix Therapeutics
$31.03 /

-0.905 (-2.83%)

Over a month ago
Conference/Events
Catalyst Biosciences to host research and development conference call » 11:25
12/14/20
12/14
11:25
12/14/20
11:25
CBIO

Catalyst Biosciences

$6.72 /

+0.52 (+8.39%)

Management holds a…

Management holds a Research & Development conference call on the Company's systemic complement regulator programs on December 14 at 12 pm. Webcast Link

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$6.72 /

+0.52 (+8.39%)

CBIO Catalyst Biosciences
$6.72 /

+0.52 (+8.39%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$6.72 /

+0.52 (+8.39%)

  • 18
    Jun
  • 13
    Feb
CBIO Catalyst Biosciences
$6.72 /

+0.52 (+8.39%)

Conference/Events
Catalyst Biosciences to host research and development conference call » 04:55
12/14/20
12/14
04:55
12/14/20
04:55
CBIO

Catalyst Biosciences

$6.20 /

-0.06 (-0.96%)

Management holds a…

Management holds a Research & Development conference call on the Company's systemic complement regulator programs on December 14 at 12 pm. Webcast Link

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$6.20 /

-0.06 (-0.96%)

CBIO Catalyst Biosciences
$6.20 /

-0.06 (-0.96%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$6.20 /

-0.06 (-0.96%)

  • 18
    Jun
  • 13
    Feb
CBIO Catalyst Biosciences
$6.20 /

-0.06 (-0.96%)

Hot Stocks
Geron opens patient screening, enrollment for IMpactMF trial » 08:32
12/11/20
12/11
08:32
12/11/20
08:32
GERN

Geron

$1.75 /

+0.02 (+1.16%)

Geron announced the…

Geron announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a telomerase inhibitor, in refractory myelofibrosis, or MF. Geron plans for IMpactMF to evaluate imetelstat compared to best available therapy in approximately 320 patients with Intermediate-2 or High-risk MF. Patients eligible for the trial will be required to be non-responsive, or refractory, to treatment with a JAK inhibitor. The primary efficacy endpoint for the Phase 3 trial is overall survival, or OS. Secondary endpoints include symptom response, spleen response, progression free survival, duration of response, safety, pharmacokinetics and patient reported outcomes. Geron plans to engage over 150 sites to participate in IMpactMF across North America, South America, Europe and Asia, with the majority of clinical sites expected to be open for screening and enrollment in 2021, subject to potential delays or interruptions associated with the evolving and uncertain effects of the COVID-19 pandemic.

ShowHide Related Items >><<
GERN Geron
$1.75 /

+0.02 (+1.16%)

GERN Geron
$1.75 /

+0.02 (+1.16%)

10/14/20 B. Riley Securities
Geron shares have 100% potential upside, says B. Riley Securities
08/26/20 H.C. Wainwright
Geron price target raised to $7 from $4 at H.C. Wainwright
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 Stifel
Geron initiated with a Buy at Stifel
GERN Geron
$1.75 /

+0.02 (+1.16%)

  • 22
    May
GERN Geron
$1.75 /

+0.02 (+1.16%)

Hot Stocks
Geron achieves 50% enrollment in IMerge Phase 3 clinical trial of imetelstat » 08:39
12/10/20
12/10
08:39
12/10/20
08:39
GERN

Geron

$1.73 /

-0.01 (-0.58%)

Geron announced…

Geron announced achievement of 50% enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes, or MDS. Data from the IMerge Phase 2 were recently presented at the American Society of Hematology Annual Meeting and support the ongoing Phase 3. The IMerge Phase 3 is a double-blind, randomized, placebo-controlled clinical trial with registration intent. The trial is designed to enroll approximately 170 transfusion dependent patients with Low or Intermediate-1 risk MDS, or lower risk MDS, who have relapsed after or are refractory to prior treatment with an erythropoiesis stimulating agent, or ESA. The primary endpoint is the rate of red blood cell, or RBC, transfusion independence, or TI, for a consecutive period of eight weeks or longer, or 8-week RBC-TI rate. Key secondary endpoints include the rate of RBC-TI of at least 24 weeks, or 24-week RBC-TI rate, rate of hematologic improvement-erythroid, defined as a reduction of at least four units of RBC transfusions over eight weeks compared with the prior RBC transfusion burden, and duration of transfusion independence. The company continues to expect full enrollment in the IMerge Phase 3 in the second quarter of 2021. As long as enrollment is completed by the end of the first half of 2021, Geron maintains its projection of top-line results from IMerge to be available in the second half of 2022.

ShowHide Related Items >><<
GERN Geron
$1.73 /

-0.01 (-0.58%)

GERN Geron
$1.73 /

-0.01 (-0.58%)

10/14/20 B. Riley Securities
Geron shares have 100% potential upside, says B. Riley Securities
08/26/20 H.C. Wainwright
Geron price target raised to $7 from $4 at H.C. Wainwright
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 Stifel
Geron initiated with a Buy at Stifel
GERN Geron
$1.73 /

-0.01 (-0.58%)

  • 22
    May
GERN Geron
$1.73 /

-0.01 (-0.58%)

Conference/Events
Catalyst Biosciences to host research and development conference call » 15:38
12/09/20
12/09
15:38
12/09/20
15:38
CBIO

Catalyst Biosciences

$5.87 /

-0.2 (-3.29%)

Management holds a…

Management holds a Research & Development conference call on the Company's systemic complement regulator programs on December 14 at 12 pm. Webcast Link

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$5.87 /

-0.2 (-3.29%)

CBIO Catalyst Biosciences
$5.87 /

-0.2 (-3.29%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$5.87 /

-0.2 (-3.29%)

  • 18
    Jun
  • 13
    Feb
CBIO Catalyst Biosciences
$5.87 /

-0.2 (-3.29%)

Syndicate
Sutro Biopharma 6M share Secondary priced at $21.00 » 06:09
12/09/20
12/09
06:09
12/09/20
06:09
STRO

Sutro Biopharma

$22.18 /

+0.27 (+1.23%)

The deal size was…

The deal size was increased to 6M share from 5M shares and priced below the last closing price of $22.22. Cowen, Piper Sandler and Wells Fargo are acting as joint book running managers for the offering.

ShowHide Related Items >><<
STRO Sutro Biopharma
$22.18 /

+0.27 (+1.23%)

STRO Sutro Biopharma
$22.18 /

+0.27 (+1.23%)

12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
STRO Sutro Biopharma
$22.18 /

+0.27 (+1.23%)

  • 09
    Dec
  • 12
    May
STRO Sutro Biopharma
$22.18 /

+0.27 (+1.23%)

STRO Sutro Biopharma
$22.18 /

+0.27 (+1.23%)

On The Fly
Fly Intel: After-Hours Movers » 18:58
12/07/20
12/07
18:58
12/07/20
18:58
SFIX

Stitch Fix

$35.77 /

+0.21 (+0.59%)

, SMAR

Smartsheet

$62.53 /

+1.11 (+1.81%)

, COUP

Coupa Software

$323.43 /

+5.32 (+1.67%)

, RTX

Raytheon Technologies

$73.03 /

-0.87 (-1.18%)

, TOL

Toll Brothers

$49.20 /

+1.29 (+2.69%)

, CASY

Casey's General Stores

$187.52 /

-3.95 (-2.06%)

, MRNS

Marinus Pharmaceuticals

$15.61 /

+1.02 (+6.99%)

, ARCT

Arcturus Therapeutics

$123.42 /

+11.15 (+9.93%)

, IBIO

iBio

$1.49 /

-0.01 (-0.67%)

, GRWG

GrowGeneration

$34.17 /

-0.81 (-2.32%)

, SQNS

Sequans

$6.10 /

+0.29 (+4.99%)

, STRO

Sutro Biopharma

$21.87 /

-0.75 (-3.32%)

Check out this evening's…

ShowHide Related Items >><<
TOL Toll Brothers
$49.20 /

+1.29 (+2.69%)

STRO Sutro Biopharma
$21.87 /

-0.75 (-3.32%)

SQNS Sequans
$6.10 /

+0.29 (+4.99%)

SMAR Smartsheet
$62.53 /

+1.11 (+1.81%)

SFIX Stitch Fix
$35.77 /

+0.21 (+0.59%)

RTX Raytheon Technologies
$73.03 /

-0.87 (-1.18%)

MRNS Marinus Pharmaceuticals
$15.61 /

+1.02 (+6.99%)

IBIO iBio
$1.49 /

-0.01 (-0.67%)

GRWG GrowGeneration
$34.17 /

-0.81 (-2.32%)

COUP Coupa Software
$323.43 /

+5.32 (+1.67%)

CASY Casey's General Stores
$187.52 /

-3.95 (-2.06%)

ARCT Arcturus Therapeutics
$123.42 /

+11.15 (+9.93%)

SFIX Stitch Fix
$35.77 /

+0.21 (+0.59%)

12/04/20
Fly Intel: Top five analyst downgrades
12/04/20 MKM Partners
Stitch Fix downgraded to Sell from Neutral at MKM Partners
12/04/20 MKM Partners
Stitch Fix downgraded to Sell from Neutral at MKM Partners
12/03/20
Fly Intel: Top five analyst downgrades
SMAR Smartsheet
$62.53 /

+1.11 (+1.81%)

09/03/20 Truist
Smartsheet price target raised to $68 from $50 at Truist
09/03/20 JPMorgan
Smartsheet price target raised to $53 from $48 at JPMorgan
09/03/20 Wells Fargo
Smartsheet price target raised to $55 from $50 at Wells Fargo
09/03/20 BMO Capital
Smartsheet price target raised to $62 from $51 at BMO Capital
COUP Coupa Software
$323.43 /

+5.32 (+1.67%)

11/12/20 Deutsche Bank
Coupa Software price target raised to $345 from $305 at Deutsche Bank
11/10/20 Berenberg
Coupa Software initiated with a Hold at Berenberg
11/03/20 Deutsche Bank
Coupa Software price target lowered to $305 from $345 at Deutsche Bank
10/23/20 Barclays
Coupa Software price target raised to $300 from $250 at Barclays
RTX Raytheon Technologies
$73.03 /

-0.87 (-1.18%)

11/10/20 JPMorgan
JPMorgan upgrades Raytheon Technologies with sector 'more investable'
11/10/20 JPMorgan
Raytheon Technologies upgraded to Overweight from Neutral at JPMorgan
10/28/20 Credit Suisse
Raytheon Technologies price target lowered to $70 from $75 at Credit Suisse
10/12/20 Credit Suisse
Raytheon Technologies price target lowered to $75 from $81 at Credit Suisse
TOL Toll Brothers
$49.20 /

+1.29 (+2.69%)

12/07/20 BTIG
Toll Brothers price target raised to $40 from $36 at BTIG
11/19/20 Truist
Toll Brothers upgraded to Buy on 'baby boomer' demand rebound at Truist
11/19/20 Truist
Toll Brothers upgraded to Buy from Hold at Truist
10/26/20 Zelman
Toll Brothers downgraded to Hold from Buy at Zelman
CASY Casey's General Stores
$187.52 /

-3.95 (-2.06%)

12/03/20 Northcoast
Casey's General Stores downgraded to Neutral from Buy at Northcoast
12/03/20 Raymond James
Casey's General Stores price target raised to $200 from $190 at Raymond James
12/01/20 Goldman Sachs
Casey's General Stores resumed with a Buy at Goldman Sachs
11/20/20 Jefferies
Casey's General Stores assumed with a Buy at Jefferies
MRNS Marinus Pharmaceuticals
$15.61 /

+1.02 (+6.99%)

11/10/20 Cantor Fitzgerald
Marinus Pharmaceuticals price target raised to $27 from $8 at Cantor Fitzgerald
09/30/20 Truist
Marinus Pharmaceuticals initiated with a Buy at Truist
09/25/20 JMP Securities
Marinus Pharmaceuticals price target raised to $26 from $7 at JMP Securities
09/23/20 Oppenheimer
Marinus Pharmaceuticals price target raised to $28 from $7 at Oppenheimer
ARCT Arcturus Therapeutics
$123.42 /

+11.15 (+9.93%)

12/07/20 B. Riley Securities
Arcturus Therapeutics price target raised to $111 from $64 at B. Riley
12/03/20 Piper Sandler
Arcturus Therapeutics price target raised to $140 from $77 at Piper Sandler
11/11/20 B. Riley Securities
Arcturus Therapeutics price target lowered to $64 from $82 at B. Riley
11/09/20 Piper Sandler
Arcturus shares down on high expectations, says Piper Sandler
IBIO iBio
$1.49 /

-0.01 (-0.67%)

11/18/20 Alliance Global Partners
iBio price target lowered to $2 from $3.10 at Alliance Global Partners
08/11/20 Alliance Global Partners
iBio price target raised to $6.65 from $2.55 at Alliance Global Partners
06/26/20 Alliance Global Partners
iBio initiated with a Buy at Alliance Global Partners
GRWG GrowGeneration
$34.17 /

-0.81 (-2.32%)

12/01/20 Lake Street
GrowGeneration price target raised to $40 from $28 at Lake Street
11/20/20 Oppenheimer
GrowGeneration price target raised to $40 from $25 at Oppenheimer
11/13/20 Stifel
GrowGeneration price target raised to $32 from $22 at Stifel
11/13/20 Lake Street
GrowGeneration price target raised to $28 from $22 at Lake Street
SQNS Sequans
$6.10 /

+0.29 (+4.99%)

10/21/20 Roth Capital
Verizon report points to solid mobile hotspot demand, says Roth Capital
09/22/20 Roth Capital
Sequans article 'steeped in ignorance' brings opportunity, says Roth Capital
06/23/20 B. Riley Securities
Sequans strategic drivers appear on track, says B. Riley FBR
05/18/20
Fly Intel: Top five analyst initiations
STRO Sutro Biopharma
$21.87 /

-0.75 (-3.32%)

12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
TOL Toll Brothers
$49.20 /

+1.29 (+2.69%)

STRO Sutro Biopharma
$21.87 /

-0.75 (-3.32%)

SQNS Sequans
$6.10 /

+0.29 (+4.99%)

SMAR Smartsheet
$62.53 /

+1.11 (+1.81%)

SFIX Stitch Fix
$35.77 /

+0.21 (+0.59%)

RTX Raytheon Technologies
$73.03 /

-0.87 (-1.18%)

MRNS Marinus Pharmaceuticals
$15.61 /

+1.02 (+6.99%)

GRWG GrowGeneration
$34.17 /

-0.81 (-2.32%)

COUP Coupa Software
$323.43 /

+5.32 (+1.67%)

CASY Casey's General Stores
$187.52 /

-3.95 (-2.06%)

ARCT Arcturus Therapeutics
$123.42 /

+11.15 (+9.93%)

  • 08
    Dec
  • 08
    Dec
  • 08
    Dec
  • 08
    Dec
  • 09
    Dec
  • 09
    Dec
  • 03
    Nov
  • 29
    Jul
  • 30
    Jun
  • 29
    May
  • 12
    May
  • 12
    May
  • 16
    Apr
  • 11
    Dec
TOL Toll Brothers
$49.20 /

+1.29 (+2.69%)

SQNS Sequans
$6.10 /

+0.29 (+4.99%)

RTX Raytheon Technologies
$73.03 /

-0.87 (-1.18%)

IBIO iBio
$1.49 /

-0.01 (-0.67%)

GRWG GrowGeneration
$34.17 /

-0.81 (-2.32%)

COUP Coupa Software
$323.43 /

+5.32 (+1.67%)

ARCT Arcturus Therapeutics
$123.42 /

+11.15 (+9.93%)

TOL Toll Brothers
$49.20 /

+1.29 (+2.69%)

STRO Sutro Biopharma
$21.87 /

-0.75 (-3.32%)

SMAR Smartsheet
$62.53 /

+1.11 (+1.81%)

SFIX Stitch Fix
$35.77 /

+0.21 (+0.59%)

RTX Raytheon Technologies
$73.03 /

-0.87 (-1.18%)

MRNS Marinus Pharmaceuticals
$15.61 /

+1.02 (+6.99%)

IBIO iBio
$1.49 /

-0.01 (-0.67%)

GRWG GrowGeneration
$34.17 /

-0.81 (-2.32%)

COUP Coupa Software
$323.43 /

+5.32 (+1.67%)

CASY Casey's General Stores
$187.52 /

-3.95 (-2.06%)

ARCT Arcturus Therapeutics
$123.42 /

+11.15 (+9.93%)

TOL Toll Brothers
$49.20 /

+1.29 (+2.69%)

STRO Sutro Biopharma
$21.87 /

-0.75 (-3.32%)

SFIX Stitch Fix
$35.77 /

+0.21 (+0.59%)

RTX Raytheon Technologies
$73.03 /

-0.87 (-1.18%)

MRNS Marinus Pharmaceuticals
$15.61 /

+1.02 (+6.99%)

IBIO iBio
$1.49 /

-0.01 (-0.67%)

GRWG GrowGeneration
$34.17 /

-0.81 (-2.32%)

COUP Coupa Software
$323.43 /

+5.32 (+1.67%)

CASY Casey's General Stores
$187.52 /

-3.95 (-2.06%)

Syndicate
Sutro Biopharma files to sell 5M shares of common stock » 16:03
12/07/20
12/07
16:03
12/07/20
16:03
STRO

Sutro Biopharma

$21.89 /

-0.73 (-3.23%)

Cowen, Piper Sandler and…

Cowen, Piper Sandler and Wells Fargo Securities are acting as joint book-running managers in the offering. Wedbush PacGrow and JMP Securities are acting as co-managers for the offering.

ShowHide Related Items >><<
STRO Sutro Biopharma
$21.89 /

-0.73 (-3.23%)

STRO Sutro Biopharma
$21.89 /

-0.73 (-3.23%)

12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
STRO Sutro Biopharma
$21.89 /

-0.73 (-3.23%)

  • 12
    May
STRO Sutro Biopharma
$21.89 /

-0.73 (-3.23%)

STRO Sutro Biopharma
$21.89 /

-0.73 (-3.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.